Equities

Santen Pharmaceutical Co Ltd

Santen Pharmaceutical Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (JPY)1,529.00
  • Today's Change6.00 / 0.39%
  • Shares traded836.10k
  • 1 Year change+32.84%
  • Beta0.6106
Data delayed at least 20 minutes, as of May 02 2024 07:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

SANTEN PHARMACEUTICAL CO., LTD. is a Japan-based pharmaceutical company engaged in the research, development, manufacturing and sales of pharmaceutical products. The Company has medical pharmaceutical business, OTC drugs business, medical devices business and other businesses. The Company engages in manufacture, sale and clinical development of medical pharmaceutical products, the development, manufacturing and sales of medical equipment, as well as the cleaning business. The Company operates in Japan, Europe, Asia, North America markets.

  • Revenue in JPY (TTM)302.08bn
  • Net income in JPY27.72bn
  • Incorporated1925
  • Employees4.14k
  • Location
    Santen Pharmaceutical Co Ltd3-9-19, Shimo-Shinjo, Higashiyodogawa-kuOSAKA-SHI 530-8552JapanJPN
  • Phone+81 676648621
  • Fax+81 663593827
  • Websitehttps://www.santen.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Ajanta Pharma Ltd74.71bn13.62bn516.31bn7.71k38.04--32.076.9158.2458.24319.08--------5,233,334.00--16.13--19.5274.1674.0118.2319.22--100.64--15.9312.0211.92-17.504.64-7.86--
WuXi XDC Cayman Inc45.32bn6.05bn517.26bn1.18k84.134.3769.5711.410.260.261.955.00------1,948,197.00--------26.35--13.35--4.03--0.0005--114.44--82.07------
HUTCHMED (China) Ltd129.47bn15.57bn520.38bn1.99k33.654.6130.824.020.89890.89897.636.560.72587.197.693,297,830.008.76-14.3513.36-20.4354.1236.5712.06-31.442.60--0.1038--96.5231.38127.93--38.65--
Gland Pharma Ltd90.92bn12.19bn521.66bn4.59k42.80--29.725.7439.9839.98298.11--------10,713,810.00--15.16--16.6960.5453.9713.4126.07--46.26--0.00-17.6417.43-35.5419.4621.24--
RemeGen Co Ltd22.96bn-32.25bn525.13bn3.62k--4.05--22.87-3.03-3.032.166.910.18640.40054.31321,671.80-26.17-18.66-31.75-23.7576.4881.94-140.43-102.881.31-64.320.2682--40.16148.65-51.30--59.07--
Xiamen Amoytop Biotech Co Ltd47.50bn12.80bn525.16bn1.96k41.0212.28--11.061.481.485.474.931.040.85416.701,135,877.0028.0917.9632.7221.0293.1790.4826.9519.173.22--0.003726.9537.5536.1993.52103.2881.61--
Zhejiang Huahai Pharmaceutical Co., Ltd.186.64bn19.81bn529.78bn8.22k26.212.91--2.840.63910.63916.025.760.45111.083.461,064,162.004.765.676.908.0759.4460.5210.5511.610.84515.480.504733.550.519910.28-28.8850.517.21--
Shanghai Junshi Biosciences Co Ltd34.74bn-43.16bn543.72bn2.57k--4.32--15.65-2.06-2.061.666.970.13481.054.11634,034.10-18.18-18.87-23.17-23.1164.0569.13-134.86-88.411.91-215.800.3018--3.38248.394.38--8.36--
J B Chemicals and Pharmaceuticals Ltd62.65bn9.52bn547.27bn5.10k58.38--45.958.7432.6332.63214.87--------6,643,323.00--15.37--18.1865.8360.2015.1915.49--15.00--31.7329.9117.366.3524.2683.8454.75
Glenmark Pharmaceuticals Ltd217.49bn-22.78bn552.16bn15.56k------2.54-43.61-25.22416.16--------7,553,779.00--4.65--6.4661.0860.78-9.726.46--1.10--10.17-5.864.94-118.02---10.274.56
Santen Pharmaceutical Co Ltd302.08bn27.72bn554.37bn4.14k20.041.8512.211.8475.9875.98823.09822.490.71252.833.3772,896,720.006.533.628.114.4460.5760.149.165.901.9412.700.171974.514.804.40-154.96--19.874.24
Bluestar Adisseo Co288.60bn6.99bn571.03bn2.73k81.701.77--1.980.12220.12225.045.630.62864.677.334,947,799.001.525.281.856.9423.8130.312.428.761.044.300.132521.81-9.262.92-95.82-43.752.74-19.09
Kangmei Pharmaceutical Co Ltd103.98bn2.19bn588.60bn4.41k267.833.89--5.660.00740.00740.35350.51110.3311.402.441,105,470.000.7034-17.601.08-32.2422.69-72.782.12-101.190.8902--0.1512--16.60-22.17103.81-22.83-53.51--
Shanghai Allist Pharmaceuticals Co Ltd34.59bn10.39bn596.00bn870.0057.367.66--17.231.081.083.608.100.45131.969.771,863,318.0013.56-6.7014.46-7.3894.9496.6330.04-49.488.50--0.0006--49.22152.37614.22--152.72--
Data as of May 02 2024. Currency figures normalised to Santen Pharmaceutical Co Ltd's reporting currency: Japanese Yen JPY

Institutional shareholders

32.66%Per cent of shares held by top holders
HolderShares% Held
Nomura Asset Management Co., Ltd.as of 15 Sep 202322.91m6.30%
Black Creek Investment Management, Inc.as of 31 Mar 202320.84m5.73%
Silchester International Investors LLPas of 19 Apr 202418.29m5.03%
Sumitomo Mitsui Trust Asset Management Co., Ltd.as of 31 Aug 202311.34m3.12%
The Vanguard Group, Inc.as of 05 Apr 202410.36m2.85%
Norges Bank Investment Managementas of 31 Dec 20239.11m2.50%
Massachusetts Financial Services Co.as of 31 Mar 20248.56m2.35%
Nikko Asset Management Co., Ltd.as of 31 Aug 20238.20m2.25%
Daiwa Asset Management Co. Ltd.as of 29 Mar 20245.12m1.41%
Goldman Sachs Asset Management LPas of 25 Apr 20244.13m1.14%
More ▼
Data from 31 Dec 2023 - 25 Apr 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.